Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.

Background: Alcohol use disorder (AUD) is a common comorbidity in patients with schizophrenia. Although pharmacological options for the management of each disease exist separately, there is no agent approved for both. Moreover, studies conducted in this patient population, who face practical and soc...

Descripción completa

Detalles Bibliográficos
Publicado en:Innovations in Clinical Neuroscience Vol. 16; no. 5/6; pp. 15 - 22
Autores principales: CITROME, LESLIE, O'MALLEY, STEPHANIE S., MCDONNELL, DAVID, YING JIANG, SIMMONS, ADAM C., BERRY, MARK P., DIPETRILLO, LAUREN E.
Formato: pictorial research tables/charts randomized controlled trial Journal Article
Publicado: Matrix Medical Communications, LLC May/Jun2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137491486&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 137491486
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        21588333
        DAD5
      jtl: Innovations in Clinical Neuroscience
      issn: 21588333
      maglogo: N
    pubinfo:
      dt: May/Jun2019
      vid: 16
      iid: 5/6
      pid: 33670
      pub: Matrix Medical Communications, LLC
      place: West Chester, Pennsylvania
    artinfo:
      ui:
        137491486
        137491486
        137491486
        137491486
      ppf: 15
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
      aug:
        au:
          CITROME, LESLIE
          O'MALLEY, STEPHANIE S.
          MCDONNELL, DAVID
          YING JIANG
          SIMMONS, ADAM C.
          BERRY, MARK P.
          DIPETRILLO, LAUREN E.
        affil: Department of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York
      sug:
        subj:
          Schizophrenia Diagnosis
          Comorbidity
          Alcoholism Drug Therapy
          Schizophrenia Drug Therapy
          Drug Therapy, Combination
          Human
          Adult
          Outpatients
          Double-Blind Studies
          Randomized Controlled Trials
          Random Assignment
          Weight Gain
          Antipsychotic Agents
          Symptom Distress
          Olanzapine
          Narcotic Antagonists
          Drinking Behavior
          Drug Tolerance
          Funding Source
          Adult: 19-44 years
      ab: Background: Alcohol use disorder (AUD) is a common comorbidity in patients with schizophrenia. Although pharmacological options for the management of each disease exist separately, there is no agent approved for both. Moreover, studies conducted in this patient population, who face practical and social challenges as a consequence of being diagnosed with schizophrenia and comorbid AUD, are limited. Methods: We describe the design of a Phase II, double-blind, randomized trial to evaluate adult outpatients with schizophrenia and comorbid AUD receiving a combination of olanzapine plus samidorphan (OLZ+SAM; ALKS 3831), a novel entity currently under development for the treatment of schizophrenia. The combination drug formulation of OLZ+SAM is intended to provide the antipsychotic efficacy of OLZ while mitigating the weight gain and concomitant metabolic abnormalities commonly associated with OLZ alone. In considering this patient population, the novel primary efficacy endpoint is the time from randomization to the first event of exacerbation of disease symptoms (EEDS) based on the occurrence of any of eight prespecified events related to worsening of disease symptoms and/or AUD, as confirmed by a blinded independent adjudication committee. The rate and number of EEDS, improvement in drinking level, and the safety and tolerability of OLZ in combination with SAM will also be assessed. Discussion: A limited number of studies have been conducted in patients with schizophrenia and AUD, and the need for further research in this difficult-tostudy population is well documented. This study is, to our knowledge, the largest and longest trial with a randomized, double-blind, active-controlled design. In addition to providing evidence for the development of OLZ+SAM (ALKS 3831) as a therapeutic option, the study aims to provide insights into the clinical management of subjects with schizophrenia and comorbid AUD.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N